NCT05221333UnknownNot Applicable
Assessment of Safety and Performance of an Investigational Wearable Injector in Healthy Volunteers
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Eitan Medical
- Enrollment
- 20
- Locations
- 2
- Primary Endpoint
- Reliability of SWI
Study Overview
Brief Summary
A prospective, open-label, single-center pilot study to evaluate the performance, safety and usability of the investigational SWI Device in healthy volunteers.
Detailed Description
A prospective, open-label, single-center pilot study to evaluate the performance, safety and usability of the investigational SWI Device in healthy volunteers.
The study will enroll up to 25 healthy adult subjects. Each subject will perform a maximum of 5 visits during the study over a period of approximately 2 months; a virtual visit for informed consent, two in-person visits for device evaluation, and two follow-up virtual visits to evaluate the skin and surrounding tissue for adverse events.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 40 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age 18 to ≤ 40 years.
- •Subject understands the English language, understands the risks, benefits, and alternatives to this research study, and is willing and able to give written informed consent.
- •Subject has no active signs/symptoms of a viral infection for 10 days prior to visit #
- •Body Mass Index between 20 to 35 kg/m2 (inclusive).
- •Subject willing and able to comply with study procedures.
- •American Society of Anaesthesiology Physical status (ASA PS) classification 1
Exclusion Criteria
- •Current use of aspirin at a daily dose > 81 mg,
- •Current use of any medication that may adversely affect blood coagulation (i.e. warfarin, Xarelto, Eliquis etc.)
- •Presence of any tattoos, discoloration, acne, scars, bruises, cuts, abrasions, rashes, hernias, or inflammation within the skin or subcutaneous tissue of the abdomen that could interfere with the infusion of saline or observation of study results, at the discretion of the investigator..
- •History of significant skin allergy, irritation, or hypersensitivity to medical adhesives or adhesive tape.
- •History of significant allergic reaction to medical saline solution.
- •History of significant allergic reaction to the skin antiseptic solutions alcohol or chlorhexidine.
- •History of any neurologic disease that may affect the perception of pain/discomfort (stroke, peripheral neuropathy).
- •Current use of any medication that may affect the perception of pain/discomfort (opioids, NSAIDs, topical local anesthetics) at the discretion of the investigator.
- •Current use of any medical condition or medication that to the opinion of the investigator may affect the risk for a serious adverse event
- •Female of childbearing age with a positive pregnant test, or currently breast feeding.
- •Study subject refuses to allow clipping of excess abdominal hair at the site of device placement
- •Any current or unstable cardiac, pulmonary, hepatic, renal, neurologic, gastrointestinal, endocrine, immune, endocrine, musculoskeletal, coagulation disorder, or infectious disease which in the opinion of the Investigator would place the subject at risk or influence the conduct of the study, or interpretation of the results.
- •Current participation in another clinical drug or device study.
- •Inability of the subject to comply with all study procedures.
- •Inability of the subject to understand the information required for monitoring their infusion sites.
Outcomes
Primary Outcomes
Reliability of SWI
Time Frame: 24 hours
70% successful injection confirmed by visual inspection of investigator
Secondary Outcomes
- Incidences of Treatment Emergent Adverse Events of SWI(1 month)
- Pain associated with use of SWI(1 month)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Not Applicable
A Pilot Study With the IDEAL TM Bioabsorbable Coronary Stent Platform Eluting Sirolimus (WHISPER)Coronary Artery DiseaseACTRN12608000373370Bioabsorbable Therapuetics, LTD60
Terminated
Phase 1
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaGlioblastomaNCT03422094Washington University School of Medicine3
Completed
Not Applicable
Evaluation of the Safety, Effectiveness & Usability of the XACT Robotic System for Image Guided Percutaneous ProceduresCT-guided Minimally Invasive Procedures e.g., BiopsiesNCT03008603Xact Robotics Ltd.60
Unknown
Not Applicable
Robotic-assisted Percutaneous Transhepatic PunctureLiver DiseasesNCT06195917Zhongda Hospital20
Withdrawn
Not Applicable
Evaluation of the XACT Robotic System for Image-guided Percutaneous Lung ProceduresCT-guided Minimally Invasive Procedures e.g. BiopsiesNCT04612985Xact Robotics Ltd.